News Briefing channel feed

Ex-CEO at Chi­na Bi­o­log­ic spear­heads $3.9B buy­out of­fer; Sy­neos ac­quires Ki­napse, adding 600 staffers

7 years ago

Pfiz­er spells out PhI­II ta­la­zoparib da­ta in NE­JM ar­ti­cle; Tolero teams up with Ab­b­Vie for AML com­bo

7 years ago

Sarep­ta CEO Doug In­gram buys $2M batch of his biotech's stock; Ex­press Scripts ex­plor­ing ex­clu­sive gene ther­a­py deals

7 years ago

Black­stone in­vests $400M in one of Chi­na's fast-grow­ing phar­ma com­pa­nies; CVS sets up an ICER-based for­mu­la­ry

7 years ago

Acor­da CTO Baty­cky is jump­ing ship to run a biotech; Mo­tif gets a PDU­FA date

7 years ago

Af­ter in­sid­er trad­ing scan­dal, US con­gress­man drops cam­paign — but stays on the bal­lot; Jun­shi Bio­sciences ap­plies for Hong Kong IPO

7 years ago

Af­ter mixed pipeline up­dates, Re­genXBio to raise $175M in of­fer­ing; Bio­Elec­tron clos­es $40M to prep late-stage mi­to­chon­dr­i­al drug

7 years ago

Lig­and ac­quires Ver­nalis at bar­gain price of $43M; Pfiz­er, No­vo back $60M round for dwarfism biotech

7 years ago

Prof­its sink­ing, My­lan looks to strate­gic al­ter­na­tives; No­vo posts de­press­ing Q2

7 years ago

Al­ler­gan picks up op­tion for Ed­i­tas' rare eye dis­ease drug; Cure­Ge­net­ics bags $17M

7 years ago

Pro­tag­o­nist rais­es $22M to re­vive PTG-100; Paratek's an­tibi­ot­ic shows non-in­fe­ri­or­i­ty

7 years ago

That big HKEX biotech boom is start­ing to look shaky; Al­ny­lam gets a green light in the UK for patisir­an

7 years ago

Te­va falls on dis­ap­point­ing sales fore­cast; Akcea and PTC take two drugs to Latin Amer­i­ca

7 years ago

Mod­er­na's Ted Ash­burn jumps to the helm at On­corus; Ar­row­head pock­ets $10M as Am­gen dos­es first pa­tient with its car­dio drug

7 years ago

Pfiz­er dumps 3 projects in Q2 pipeline prun­ing; Te­va seals 12-year lease on new NJ head­quar­ters

7 years ago

Red­hill spikes — briefly — on pos­i­tive Crohn's da­ta; Dai­ichi inks glob­al li­cens­ing deal with Gly­co­tope

7 years ago

CHMP rec­om­mends OK for Al­ny­lam's patisir­an; Am­gen scraps a BC­MA ADC

7 years ago

Chi­nese reg­u­la­tors green light Mer­ck­'s Keytru­da in record time; As­traZeneca takes the price-freeze pledge

7 years ago

Pfiz­er plans $465M man­u­fac­tur­ing fa­cil­i­ty at Michi­gan base; Chi­na's Ts­inghua Uni­ver­si­ty inks dis­cov­ery deal with Bris­tol-My­ers

7 years ago

Mer­ck hands Sutro $60M to start on im­munomod­u­la­to­ry drug dis­cov­ery; Eli Lil­ly spin­ning out an­i­mal health group

7 years ago

Pfiz­er/Mer­ck KGaA launch sol­id tu­mor com­bo study with Leap; As­traZeneca and Im­munomedics to test ADC can­cer com­bo

7 years ago

BMS part­ners with Grit­stone on sol­id tu­mor com­bos; Roche's Alzheimer's di­ag­nos­tic gets break­through sta­tus

7 years ago

Ipsen adds cowork­ing to new Boston HQ with Bi­o­Labs part­ner­ship; NYC gets biotech start­up ac­cel­er­a­tor, fund­ed with $25M from state

7 years ago

Cel­lec­tar climbs (then sinks) on PhII DL­B­CL da­ta; Vyr­i­ad inks deal with Pfiz­er/Mer­ck KGaA

7 years ago
First page Previous page 57585960616263 Next page Last page
A service from the Financial Times